Precision Health Clinical Trials

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Conditions:   Clear Cell Papillary Renal Neoplasm;   Collecting Duct Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Carcinoma;   Hereditary Papillary Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma;   Metastatic Unclassified Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8;   Stage IV Renal Cell Cancer AJCC v8;   Tubulocystic Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
Interventions:   Drug: Pamiparib;   Drug: Temozolomide
Sponsors:   Jonsson Comprehensive Cancer Center;   BeiGene;   Driven To Cure

Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)

Conditions:   Head and Neck Cancer;   Advanced Cancer;   Metastatic Cancer;   HNSCC;   Squamous Cell Carcinoma
Sponsors:   University Health Network, Toronto;   Princess Margaret Hospital, Canada

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Conditions:   BRCA1 Mutation;   BRCA2 Mutation;   Ovarian Cancer;   Fallopian Tube Cancer;   High Grade Serous Carcinoma
Intervention:   Drug: Talazoparib Oral Capsule
Sponsors:   Brown University;   Pfizer;   Lifespan

SH-DS01 on Fecal Metagenomic Stability

Condition:   Irritable Bowel Syndrome
Intervention:   Drug: DS-01
Sponsors:   Beth Israel Deaconess Medical Center;   Seed Health

Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma (PRE-MERIDIAN)

Conditions:   Cancer;   Head and Neck Squamous Cell Carcinoma;   Head and Neck Cancer
Sponsors:   University Health Network, Toronto;   Princess Margaret Hospital, Canada

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

Condition:   Metastatic Castration-sensitive Prostate Cancer
Intervention:   Drug: Apalutamide
Sponsors:   Kindai University;   Janssen Pharmaceutical K.K.

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

Conditions:   Biliary Tract Neoplasms;   Gastric Cancer;   Esophageal Squamous Cell Carcinoma;   Colorectal Cancer;   Gastrointestinal Stromal Tumors;   Pancreatic Cancer;   Neuroendocrine Tumors;   Unknown Primary Cancer;   Digestive Cancer
Interventions:   Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.;   Drug: Other Therapy
Sponsors:   Peking University;   Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China

UW Undiagnosed Genetic Diseases Program

Conditions:   Rare Diseases;   Genetic Disease;   Undiagnosed Disease
Intervention:   Diagnostic Test: Trio Whole Genome Sequencing and Participant-Specific Research
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin Center for Human Genomics and Precision Medicine

Transcriptional and Immine Parameters of Response to Belinumab

Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Belimumab
Sponsor:   Biomedical Research Foundation, Academy of Athens
Not yet recruiting

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Gallbladder Cancer;   Intrahepatic Cholangiocarcinoma;   Perihilar Cholangiocarcinoma;   Extrahepatic Cholangiocarcinoma;   Hilar Cholangiocarcinoma;   Distal Bile Duct Cancer
Intervention:   Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors:   University of Washington;   Natera, Inc.;   SEngine Precision Medicine, Inc.